Newborn Screening for SCD in the USA and Canada

Sickle cell disease (SCD) encompasses a group of inherited red cell disorders characterized by an abnormal hemoglobin, Hb S. The most common forms of SCD in the United States and Canada are identified through universal newborn screening (NBS) programs. Now carried out in all fifty U.S. states and 8 Canadian provinces, NBS for SCD represents one of the major public health advances in North America. The current status of NBS programs for hemoglobinopathies and the screening techniques employed in many regions worldwide reflect in large part the U.S. and Canadian experiences. Although the structure, screening algorithms and laboratory procedures, as well as reporting and follow up, vary between NBS programs, the overall workflow is similar. The current review summarized the historical background, current approaches, and methods used to screen newborns for SCD in the United States and Canada.

[1]  A. King,et al.  The sickle cell disease implementation consortium: Translating evidence‐based guidelines into practice for sickle cell disease , 2018, American journal of hematology.

[2]  R. Parad,et al.  Case Definitions for Conditions Identified by Newborn Screening Public Health Surveillance , 2018, International journal of neonatal screening.

[3]  A. Hennis,et al.  Chronic Disease Challenges in the Caribbean. , 2016, Global heart.

[4]  F. Piel.  The Present and Future Global Burden of the Inherited Disorders of Hemoglobin. , 2016, Hematology/oncology clinics of North America.

[5]  J. Eckman,et al.  Newborn screening for sickle cell diseases in the United States: A review of data spanning 2 decades. , 2015, Seminars in perinatology.

[6]  E. Vichinsky,et al.  Population based surveillance in sickle cell disease: Methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH) , 2014, Pediatric blood & cancer.

[7]  B. Adam,et al.  Stabilities of intact hemoglobin molecules and hemoglobin peptides in dried blood samples. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[8]  A. Tatem,et al.  Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000 , 2014, The Lancet. Global health.

[9]  H. Sox.  Resolving the tension between population health and individual health care. , 2013, JAMA.

[10]  S. Shahangian,et al.  CDC Recommendations: Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders. , 2012, Clinical chemistry.

[11]  Mingzeng Sun,et al.  Long-term follow-up of children with confirmed newborn screening disorders using record linkage , 2011, Genetics in Medicine.

[12]  A. Kemper,et al.  What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children , 2011, Genetics in Medicine.

[13]  F. Lorey,et al.  The context and approach for the California newborn screening short- and long-term follow-up data system: Preliminary findings , 2010, Genetics in Medicine.

[14]  K. Hassell.  Population estimates of sickle cell disease in the U.S. , 2010, American journal of preventive medicine.

[15]  B. Therrell,et al.  History and current status of newborn screening for hemoglobinopathies. , 2010, Seminars in perinatology.

[16]  Sharon F Terry,et al.  Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children , 2010, Genetics in Medicine.

[17]  V. Bours,et al.  Newborn screening for sickle cell disease using tandem mass spectrometry. , 2008, Clinical chemistry.

[18]  A. Kemper,et al.  Long-term follow-up after diagnosis resulting from newborn screening: Statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children , 2008, Genetics in Medicine.

[19]  C. J. Wang,et al.  Communication of positive newborn screening results for sickle cell disease and sickle cell trait: Variation across states , 2008, American journal of medical genetics. Part C, Seminars in medical genetics.

[20]  B. Therrell,et al.  Newborn screening in North America , 2007, Journal of Inherited Metabolic Disease.

[21]  H. Pearson,et al.  Newborn screening coupled with comprehensive follow-up reduced early mortality of sickle cell disease in Connecticut. , 2007, Connecticut medicine.

[22]  Michael S. Watson,et al.  Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary , 2006, Pediatrics.

[23]  E. Delvin,et al.  Newborn screening for sickle cell disease: A 1988-2003 Quebec experience. , 2006, Paediatrics & child health.

[24]  W. H. Hannon,et al.  National evaluation of US newborn screening system components. , 2006, Mental retardation and developmental disabilities research reviews.

[25]  P. Frenette.  Sickle cell vaso-occlusion: multistep and multicellular paradigm , 2002, Current opinion in hematology.

[26]  S. Davies,et al.  Evaluation of cation-exchange HPLC compared with isoelectric focusing for neonatal hemoglobinopathy screening. , 1999, Clinical chemistry.

[27]  M. Natowicz,et al.  Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States. , 1997, American journal of public health.

[28]  C. Pegelow,et al.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. , 1995, Blood.

[29]  J. Selekman.  Update: new guidelines for the treatment of infants with sickle cell disease. Agency for Health Care Policy and Research. , 1993, Pediatric nursing.

[30]  J. Smith,et al.  Sickle cell disease: screening and management in newborns and infants. Agency for Health Care Policy and Research. , 1993, American family physician.

[31]  E. Vichinsky.  Comprehensive care in sickle cell disease: its impact on morbidity and mortality. , 1991, Seminars in hematology.

[32]  T L Chorba,et al.  Case definitions for public health surveillance. , 1990, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[33]  M. Gaston,et al.  Newborn screening for sickle cell disease and other hemoglobinopathies. , 1989, Pediatrics.

[34]  E. Vichinsky,et al.  Newborn screening for sickle cell disease: effect on mortality. , 1988, Pediatrics.

[35]  T. Huisman,et al.  Separation of hemoglobins and hemoglobin chains by high-performance liquid chromatography. , 1987, Journal of chromatography.

[36]  E Vichinsky,et al.  Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. , 1986, The New England journal of medicine.

[37]  D. Higgs,et al.  Acute splenic sequestration in homozygous sickle cell disease: natural history and management. , 1985, The Journal of pediatrics.

[38]  A. Schechter,et al.  Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. , 1985, Blood.

[39]  R. Grover,et al.  Current sickle cell screening program for newborns in New York City, 1979-1980. , 1983, American journal of public health.

[40]  R. M. Schmidt.  Hemoglobinopathy screening: approaches to diagnosis, education and counseling. , 1974, American journal of public health.

[41]  P. Dembure,et al.  Sickle-cell anemia and other hemoglobinopathies. Procedures and strategy for screening employing spots of blood on filter paper as specimens. , 1973, The New England journal of medicine.